MediWound (NASDAQ:MDWD) Upgraded to Sell at StockNews.com

MediWound (NASDAQ:MDWD) was upgraded by investment analysts at StockNews.com to a “sell” rating in a research report issued to clients and investors on Friday.

Other equities analysts have also recently issued reports about the company. HC Wainwright restated a “buy” rating and set a $25.00 price objective on shares of MediWound in a research note on Thursday. Craig Hallum started coverage on MediWound in a research note on Friday, February 28th. They set a “buy” rating and a $39.00 price objective on the stock.

MediWound Price Performance

MDWD traded down $0.78 during trading hours on Friday, hitting $16.27. 239,922 shares of the stock were exchanged, compared to its average volume of 90,964. The stock has a 50-day simple moving average of $18.17 and a 200-day simple moving average of $17.58. MediWound has a 12 month low of $12.78 and a 12 month high of $24.00. The stock has a market cap of $175.49 million, a price-to-earnings ratio of -5.61 and a beta of 0.82.

MediWound (NASDAQ:MDWD) last announced its quarterly earnings data on Wednesday, March 19th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.59) by $0.23. MediWound had a negative return on equity of 82.17% and a negative net margin of 142.29%. The firm had revenue of $5.84 million for the quarter, compared to analysts’ expectations of $5.79 million. During the same period last year, the business posted ($0.19) earnings per share. Sell-side analysts expect that MediWound will post -2.66 EPS for the current year.

Institutional Investors Weigh In On MediWound

A number of hedge funds have recently added to or reduced their stakes in the stock. Investor AB bought a new stake in MediWound in the third quarter valued at $15,750,000. Yelin Lapidot Holdings Management Ltd. lifted its stake in MediWound by 13.4% in the fourth quarter. Yelin Lapidot Holdings Management Ltd. now owns 851,361 shares of the biopharmaceutical company’s stock valued at $15,154,000 after buying an additional 100,618 shares during the last quarter. Essex Investment Management Co. LLC lifted its stake in MediWound by 30.7% in the fourth quarter. Essex Investment Management Co. LLC now owns 148,949 shares of the biopharmaceutical company’s stock valued at $2,651,000 after buying an additional 35,012 shares during the last quarter. Northern Trust Corp lifted its stake in MediWound by 94.6% in the fourth quarter. Northern Trust Corp now owns 144,768 shares of the biopharmaceutical company’s stock valued at $2,577,000 after buying an additional 70,367 shares during the last quarter. Finally, Sargent Investment Group LLC lifted its stake in MediWound by 3.4% in the fourth quarter. Sargent Investment Group LLC now owns 121,190 shares of the biopharmaceutical company’s stock valued at $2,217,000 after buying an additional 3,998 shares during the last quarter. 46.83% of the stock is currently owned by institutional investors.

MediWound Company Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.